Uniqure NV

uniQure reports strong Q2 2026 results with key regulatory milestones for AMT-130, a strengthened financial position extending cash runway to 2030, and positive early data for AMT-260.

uniQure N.V. has priced an upsized public offering of 4,945,055 ordinary shares at $45.50 per share, with underwriters fully exercising their option for additional shares.

uniQure announced its plan to submit a Biologics License Application (BLA) for its Huntington's disease gene therapy, AMT-130, in the third quarter of 2026, following FDA agreement on using 3-year Phase I/II data for accelerated approval.

uniQure N.V. shareholders approved amendments to the 2014 Share Incentive Plan and changes to the company's articles of association, including an exclusive forum selection clause.

uniQure reports Q1 2026 financial results, highlighting progress in its gene therapy pipeline, particularly for Huntington's disease, while navigating regulatory feedback from the FDA.

uniQure N.V. announced a successful pre-submission meeting with the UK MHRA for its Huntington's disease gene therapy, AMT-130, targeting a Q3 2026 Marketing Authorization Application submission.

uniQure N.V. reports increased cash reserves and ongoing clinical trial progress, alongside a significant net loss for Q2 2026.

uniQure N.V. reported its first-quarter 2026 financial results, highlighting increased license revenues but also a significant regulatory hurdle for its lead Huntington's disease candidate, AMT-130.

uniQure N.V. reported mixed Q3 2025 results, with a significant increase in cash from recent offerings, but a major setback in its lead Huntington's disease program, AMT-130, due to FDA feedback.

uniQure N.V. reported a reduced net loss and extended its cash runway into the second half of 2027, driven by a recent public offering and significant regulatory and clinical advancements for its lead Huntington's disease program, AMT-130, despite a decline in total revenues due to divestment.

uniQure N.V. announces its Q1 2025 financial results, highlighting progress in its gene therapy pipeline, particularly the Huntington's disease program, and providing an update on its financial position.

uniQure N.V. announced its third-quarter 2024 results, showcasing advancements in its gene therapy programs and the completion of a strategic restructuring.

uniQure N.V. reported positive topline data for its lead Huntington's disease gene therapy, AMT-130, but the FDA deemed the current Phase I/II data insufficient for a Biologics License Application (BLA) submission, recommending a randomized, double-blind, sham surgery-controlled study.

uniQure N.V. details its 2024 financial results and provides updates on its gene therapy programs, including progress on AMT-130 for Huntington's disease and other clinical candidates.

uniQure N.V. details its share structure, director duties, and shareholder rights under Dutch law, contrasting them with Delaware corporate law in a recent SEC filing.

uniQure N.V. CEO Matthew C. Kapusta reported transactions involving the sale of ordinary shares and the acquisition of shares through a stock option, all executed under a pre-arranged 10b5-1 trading plan.

Walid Abi-Saab, Chief Medical Officer at uniQure N.V., reported transactions involving the sale of ordinary shares and the acquisition of stock options under a pre-arranged trading plan.

uniQure N.V. Director Jack Kaye reports transactions involving the purchase and sale of ordinary shares, executed under a Rule 10b5-1 trading plan.

Walid Abi-Saab, Chief Medical Officer at uniQure N.V., reported the sale of 1,434 ordinary shares to cover tax withholding obligations upon the vesting of restricted share units.

uniQure N.V. CEO Matthew C. Kapusta executed a series of transactions involving the purchase and sale of company stock under a pre-arranged trading plan.

Director Madhavan Balachandran exercised options and sold 10,000 shares of uniQure N.V. under a Rule 10b5-1 trading plan.

uniQure N.V. has announced its 2026 Annual General Meeting of Shareholders will be held on June 10, 2026, to vote on key corporate matters including director reappointments, auditor appointment, and amendments to its articles of association.

uniQure N.V. will hold its Annual General Meeting on June 11, 2025, in Amsterdam, to vote on proposals including the adoption of annual accounts, director reappointments, and auditor appointment.

uniQure N.V. has released its definitive proxy statement outlining proposals for the 2025 Annual General Meeting of Shareholders, including director reappointments, share authorizations, and executive compensation.

uniQure N.V. will hold its Annual General Meeting on June 18, 2024, in Amsterdam, with proposals including the adoption of annual accounts, director reappointment, and share issuance authorization.

uniQure N.V. will hold its 2024 Annual General Meeting on June 18, 2024, to vote on key proposals including director reappointments, share issuance authorizations, and executive compensation.

Aberdeen Group plc and abrdn Inc. have reported a combined beneficial ownership of 4.52% in uniQure N.V. ordinary shares as of June 30, 2026.

JPMorgan Chase & Co. has reported beneficial ownership of 7.0% of uniQure N.V.'s ordinary shares as of June 30, 2026.

RTW Investments, LP and Roderick Wong have reported beneficial ownership of 4.1% of uniQure N.V.'s ordinary shares as of March 31, 2026.

State Street Corporation has reported beneficial ownership of 3.6% of Uniqure NV's common stock as of March 31, 2026.

FMR LLC and Abigail P. Johnson have filed a Schedule 13G, reporting beneficial ownership of 2.8% of Uniqure N.V.'s common stock as of March 31, 2026.

Avoro Capital Advisors and Behzad Aghazadeh have reported a 9.87% beneficial ownership stake in uniQure N.V., holding 6,150,000 ordinary shares.